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Résumé 
Objectif: Évaluer la relation entre la fonction cognitive chez les personnes âgées atteintes de 
dégénérescence maculaire reliée à l’âge (DMLA), de glaucome ou de dystrophie cornéenne de 
Fuchs et les comparer avec les personnes âgées n’ayant pas de maladie oculaire.   
Devis: Étude transversale de population hospitalière.  
Participants: 420 participants (113 avec la DMLA, 66 avec la dystrophie cornéenne de Fuchs, 
130 avec le glaucome et 111 témoins). 
Méthodes: Nous avons recruté les patients à partir de la clinique d’ophtalmologie de l’Hôpital 
Maisonneuve-Rosemont (Montréal, Canada) de septembre 2009 à septembre 2013.  Les patients 
atteints de la DMLA ou de la maladie de Fuchs ont une acuité visuelle inférieure à 20/40 dans 
les deux yeux, tandis que les patients avec du glaucome ont un champ visuel dans le pire œil 
inférieur ou égal à -4dB.  Les patients contrôles, qui ont été recrutés à partir des mêmes cliniques, 
ont une acuité visuelle et un champ visuel normaux.  Nous avons colligé des données concernant 
la fonction cognitive à partir du test Mini-Mental State Exam (MMSE)-version aveugle.  Pour 
mesurer la fonction visuelle, nous avons mesuré l’acuité visuelle, la sensibilité au contraste et 
le champ visuel.  Nous avons également révisé le dossier médical.  Pour les analyses statistiques 
nous avons utilisé la régression linéaire.  
Critère de jugement principal: MMSE-version aveugle. 
Résultats: Les trois maladies oculaires ont été associées à une limitation de la cognition.  Le 
score de MMSE-version aveugle se situe de 0.7 à 0.8 unités plus basses par rapport au groupe 
contrôle. Comparativement aux contrôles, les patients avec maladies oculaires ont eu un score 
moyen diminué (P < 0.05).  Le niveau d’éducation élevé est associé à une meilleure cognition 
(P < 0.001). 
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Conclusions: Nos résultats suggèrent que les maladies oculaires sont associées à une diminution 
de la fonction cognitive chez les personnes âgées. De futures études sont nécessaires pour 
évaluer l’impact des maladies oculaires sur le déclin cognitif chez cette population pour pouvoir 
envisager des interventions ciblées qui pourraient les aider à maintenir leur indépendance le plus 
longtemps possible. 
Mots-clés : cognition, maladie oculaire, vieillissement 
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Abstract 
Objective:  To examine the extent of cognitive impairment in patients with age-related 
macular degeneration (AMD), glaucoma, or Fuchs corneal dystrophy as compared to a control 
group of older adults with good vision.   
Design:  Cross-sectional hospital-based study. 
Participants: 420 people (113 with AMD, 66 with Fuchs, 130 with glaucoma, and 111 
controls). 
Methods: Patients were recruited from the ophthalmology clinic of Maisonneuve-Rosemont 
Hospital (Montreal, Canada) from September 2009 until September 2013.  Patients with AMD 
and Fuchs had to have visual acuity in the better eye of worse than 20/40 while patients with 
glaucoma had to have visual field deficit in their worse eye of at least -4dB.  Control patients 
who had normal visual acuity and visual field were recruited from the same clinic.   
Cognitive status was measured using the Mini-Mental State Exam (MMSE) Blind Version.  
Visual acuity, contrast sensitivity, and visual field were assessed, and the medical record was 
reviewed.  Linear regression was used.   
Main Outcome Measures:  Mini-Mental State Exam (MMSE) Blind Version 
Results:  The three eye diseases were associated with of cognitive impairment.  Compared to 
controls, patients with age-related eye disease had lower MMSE Blind scores (p < 0.05).  
Scores were between 0.7-0.8 units lower than the control group.  Better education was 
associated with better cognition (p < 0.001).   
Conclusions:  Our results suggest that eye diseases are associated with cognitive impairment.  
It is important to further explore the impact of eye disease on cognitive function in this 
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population in order to develop interventions that would help affected older adults maintain 
their independence. 
Keywords : cognition, eye disease, aging 
 v 
Table des matières 
 
Résumé ........................................................................................................................................ i 
Abstract ..................................................................................................................................... iii 
Table des matières ..................................................................................................................... v 
List of tables: ........................................................................................................................... vii 
List of figures .......................................................................................................................... viii 
CHAPTER I:   INTRODUCTION .......................................................................................... 1 
I.1.  Cognitive Impairment In Older Adults ............................................................................ 1 
I.2.  Specific Objectives and Hypotheses ................................................................................ 1 
I.3.  Significance of this Research .......................................................................................... 2 
I.4.  Organization of the Thesis ............................................................................................... 2 
CHAPTER II:   LITERATURE REVIEW ............................................................................ 3 
II.1.  Definition of Cognitive Impairment ............................................................................... 3 
II.2.  Measurement of Cognitive Impairment in Research ...................................................... 4 
II.3.  Frequency of Cognitive Impairment .............................................................................. 7 
II.4.  Economic Consequences of Severe Cognitive Impairment ........................................... 8 
II.5.  Disability Consequences of Cognitive Impairment ....................................................... 9 
II.6.  Prevention ............................................................................ Erreur ! Signet non défini. 
II.7.  Treatment ..................................................................................................................... 12 
II.7.1.  Alzheimer ’s disease: ............................................................................................ 12 
II.7.2.  Mild Cognitive Impairment ................................................................................... 13 
II.8.   Relation Between Eye Disease and Cognitive Decline ............................................... 15 
II.8.1.  The Three Eye Diseases ........................................................................................ 15 
II.8.2.  Studies Examining Relationship Between AMD and Cognition .......................... 24 
II.8.3.  Studies Examining Relationship Between Glaucoma and Cognition ................... 27 
II.2.3.  Need For Further Research ................................................................................... 29 
CHAPTER III       SAMPLE SIZE CALCULATION ......................................................... 29 
CHAPTER IV RESULTS ................................................................................................ 31 
ABSTRACT .......................................................................................................................... 32 
 vi 
INTRODUCTION ................................................................................................................ 33 
METHODS ........................................................................................................................... 34 
Study Design and Population ............................................................................................ 34 
Data Collection ................................................................................................................. 35 
Statistical Analysis ............................................................................................................ 37 
RESULTS ............................................................................................................................. 37 
DISCUSSION ....................................................................................................................... 38 
TABLES ............................................................................................................................... 41 
CHAPTER V  DISCUSSION ............................................................................................. 45 
V.1.  Eye Disease and Cognitive Decline ............................................................................. 45 
V.2.  Strengths and Limits of the Study ................................................................................ 46 
V.3.  Clinical Implications and Future Research .................................................................. 47 
Bibliography ............................................................................................................................ 49 
 
 
 
 
 
 
 
 
 
 
 
 vii 
List of tables:  
Table I : Description of eye disease and control groups .......................................................... 41 
Table II: Relationships between age-related eye disease and cognitive status from linear 
regression model ............................................................................................................... 43 
Table III : Multiple linear regression models showing adjusted relationship between three 
measures of visual function and cognitive status .............................................................. 44 
Table IV: Some cognitive tests used in research ........................................................................ i 
Table V: The frequency of CIND and dementia and the measurement tools used from large 
population-based studies throughout the world .................................................................. v 
 
 viii 
List of figures 
Figure 1: Mini-Mental Status Exam Blind Version – English Version ................................... vii 
Figure 2 : Mini-Mental Status Exam Blind Version – French Version .................................. viii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ix 
LIST OF ABBREVIATIONS 
 
AAMI Age-Associated memory impairment 
AChEls ACethycholinesterases inhibitors 
AD Alzheimer disease 
ADAS-cog Alzheimer Disease Assessment Scale-Cognitive Subscale 
ADL Activities of Daily Living 
aMCI amnestic MCI 
AMD Age-Related Macular Degeneration 
AMT Abbreviated Mental Test 
ANOVA Analysis of variance 
APOE Apolipoprotein 
AREDS Age-Related Eye Disease Study 
β Linear Regression Coefficient 
CAMDEX Cambridge Mental Disorder OF Eldery 
CI Confidence interval 
CIND Cognitive impairment with no dementia 
CLA Cognitive leisure activities 
CSHA Canadian Study of Health and Aging 
dB Decibel 
DSEK Descemet stripping endothelial keratoplasty 
DSST Digit Symbol Substitution Test 
ε4 Epsilon 4 
ETDRS Early Treatment of Diabetic Retinopathy Study 
FCD Fuchs’ Corneal Dystrophy 
FDT Frequency Doubling Technology 
GPCOG General Practitioner Assessment of Cognition 
HMR Hôpital Maisonneuve-Rosemont 
 x 
IADL Instrument activity of daily living 
ILSE Interdisciplinary Longitudinal Study on Adult Development 
and Aging 
IOP Intra-ocular pressure 
LALES Los Angeles Latino Eye Study 
log Logarithm 
logMAR Logarithm of Minimal Angle of Resolution 
Max Maximum 
MCI Mild cognitive impairment 
MD Mean Deviation 
MESA Multi-Ethnic Study of Atherosclerosis 
MIS Memory Impairment Screen 
MMSE Mini-Mental State Exam 
MMSE-blind Blind Version of the MMSE 
MOCA Montreal Cognitive Assessment 
3MSE Modified Mini-Mental State Examination 
n Number of subjects 
NFL Nerve Fiber Layer 
OR Odd Ratio 
P P value 
PACG Primary angle closure glaucoma 
PAR Population attributable risk 
POAG Primary Open Angle Glaucoma 
RCT Randomized Clinical Trial 
RGC Retinal ganglion cell 
RPE Retinal pigment epithelium 
SPMSQ Short Portable Mental Status Questionnaire 
SD Standard Deviation 
 xi 
UV Ultra-Violet 
WMS–R Wechsler Memory Scale–Revised 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 xii 
 
Dedication 
 
 
 
I wish to express my deepest thanks and gratitude to my supervisor Dr Ellen Freeman, 
who provided me with tight guidance and advice. I owe her a lot for the tremendous source of 
knowledge she has been to me. It was a real pleasure working with her. 
 
 
 
I want to express my deepest gratitude to my family for their continuous support, 
encouragement and sacrifice throughout the years. 
 
 
 
To my mother and father who kept me a curious mind. 
  
 xiii 
 
 
Acknowledgements 
 
 
My distinguished thanks to the members of our research group for their considerable help and 
advice in conducting my project.  
 
   
 
I would like to take this opportunity to thank for the generosity in funding to ophthalmology department 
and the FROUM Scholarship. I am very honoured to be the recipient of this award 
. 
 
 
I would also like to express my gratitude to the CNIB and CIHR for the financial support to 
conduct my master project. 
 
 
1 
 
CHAPTER I:   INTRODUCTION 
 
I.1. Cognitive impairment in older adults 
 
 Cognitive impairment is an acquired deficit in memory, problem solving, orientation, or 
abstraction1. The risk of cognitive impairment increases with older age. Other established risk 
factors for cognitive impairment identified in longitudinal studies include current smoking, 
diabetes, apolipoprotein E ε4 allele, depressive symptoms, and metabolic syndrome2. There is 
some evidence to suggest that eye disease or visual impairment may be risk factors for cognitive 
impairment although there is no consensus and the existing research has methodological 
limitations (discussed in Section II.2). There is a need for more research to determine the role 
of vision loss on cognitive function.  
 
 I.2. Specific objectives and hypotheses 
 
The goal of this research was to determine if people with eye disease have worse 
cognition than people with normal vision. We focused on eye diseases that are age-related and 
that affect different components of visual function such as age-related macular degeneration, 
glaucoma, and Fuchs corneal dystrophy. We hypothesized that people with central vision loss 
would have the worst cognition, followed by people with peripheral vision loss, followed by 
people with normal vision.   
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I.3. Significance of this research 
 
 This research is important for many reasons. If vision loss causes cognitive impairment, 
then intervention efforts need to be targeted towards people with vision loss. As the Canadian 
population ages, more and more people are going to be afflicted with age-related eye disease 
and therefore may be at risk for cognitive impairment.  
 
I.4. Organization of the thesis 
 
 This thesis is composed of 5 chapters: an introduction, a literature review, sample size 
calculation, an article that has been submitted for publication, and a discussion section.   
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CHAPTER II:   LITERATURE REVIEW 
 
II.1. Definition of cognitive impairment  
 
As mentioned above, cognitive impairment is an acquired deficit in memory, problem 
solving, orientation, or abstraction. Cognitive impairment may be caused by normal aging-
related changes or age-related diseases. There are differing severities of cognitive impairment 
that are still in the process of being defined with broad agreement. Mild cognitive impairment 
(MCI) and cognitive impairment with no dementia (CIND) are evolving terms that involve 
greater than expected cognitive decline for a person’s age and educational level and no more 
than mild functional impairment that does not yet meet the definition of dementia2. Dementia is 
impaired cognition that results in functional impairment. The major cause of dementia is 
Alzheimer’s disease accounting for about 60% of all cases. Other causes of dementia include 
stroke, brain injury, tumor, alcohol abuse, infection, and others.   
 
People with MCI are at a higher risk of developing dementia3. There are controversies 
about the definition of MCI. A multidisciplinary and a worldwide group of experts from Asia, 
Australia, Europe and North America proposed MCI general criteria such that it (i) refers to 
non-demented persons with cognitive deficits measurable in some form or another, and (ii) 
represents a clinical syndrome that can be utilized to classify persons who do not fulfil a 
diagnosis of dementia, but who have a high risk of progressing to a dementia disorder4.   
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Many different terms have been used by studies reporting MCI, e.g. cognitive 
impairment with no dementia (CIND), age-associated memory impairment (AAMI), MCI, and 
amnestic MCI (aMCI). This has caused confusion in the literature. 
 
II.2. Measurement of cognitive impairment in research 
 
There are many different diagnostic tools that have been described in the literature. There 
is no single cognitive assessment tool that is considered to be the gold standard. Many studies 
have examined tools to give a brief cognitive assessment during primary care visits.  
 
A systematic review for the U.S. Preventive Services Task Force, included 55 fair- to 
good-quality diagnostic accuracy studies of brief screening instruments that could be delivered 
by a clinician in primary care in 10 minutes or less or self-administered in 20 minutes or less5.  
The studies varied in mean age (range 69 to 95 years) and prevalence of dementia (range from 
1.2% to 47.1%). Lin et al found that the most commonly used measures were the Mini-Mental 
State Exam (MMSE) and the Alzheimer Disease Assessment Scale-Cognitive Subscale (ADAS-
cog)5. 
 
The MMSE is the most widely used. It can be administered in 5-10 minutes and consists 
of a variety of questions6. The questions have been grouped into seven categories, each 
representing a different cognitive domain: Orientation to time (five points), orientation to place 
(five points), registration of three words (three points), attention and calculation (five points), 
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recall of three words (three points), language (eight points) and visual construction (one point). 
The most common cut-off points to detect dementia are 23/24 and 24/25. The scores range from 
0 to 30. The lower the score, the cognitive impairment is important. 
  
The Alzheimer Disease Assessment Scale-Cognitive Subscale (ADAS-cog) is composed 
of 13 items7. The ADAS-cog identifies many domains: Memory word recall, following 
commands, constructional praxis, naming objects, ideational praxis, orientation, word 
recognition, recall of test instructions, spoken language ability and language, word-finding 
difficulty, comprehension, executive function and number cancellation. The total score on the 
ADAS-cog range from 0 to 70, with a higher score indicating greater cognitive impairment7. 
 
We used the the Blind Version of the MMSE (MMSE-blind) in our study, employed by 
Reischies and Geiselmann8, from which eight items involving image processing in the test 
situation (two items with naming, reading, and obeying a sentence, writing a sentence, copying, 
and three items for performing a three-stage command) had been deleted. The MMSE-blind can 
be used to assess orientation to time and place, memory, attention, calculation, and language. 
These areas of cognitive functioning have been found to have discriminative power in the 
detection of dementia. The number of items of the full MMSE was reduced by 27%, leaving a 
total possible score of 22 for the MMSE-blind. 
 
 
 6 
Busse et al examined the validity of the MMSE-blind and found that a cut-off point of 
16 had 99% sensitivity and 94% specificity.  The Test–retest reliability for the MMSE-blind 
was assessed in a sample of 35 subjects aged 75 years and older9. It was carried out within a 2-
weeks interval. Busse et al obtained a significant K value of 0.5. Increased scores on retest were 
found indicating practice effects (Wilcoxon-test, z = 2.43, P =0.015)9. 
The Alzheimer’s Association convened a group of experts to identify brief cognitive 
assessments most suitable or most used for the detection of cognitive impairment during the 
Medicare Annual Wellness in primary care settings. The experts focused on systematic evidence 
review studies published since 2000. They found that Memory Impairment Screen (MIS)10, the 
General Practitioner Assessment of Cognition (GPCOG) and the Mini-Cog11 as most suited for 
routine use in primary care12-17. 
 
Other tests that are used in research include the Montreal Cognitive Assessment 
(MOCA)18 and the Digit Symbol Substitution Test (DSST)19,20. The version of the MoCA is a 
one-page 30-point test administered in 10 minutes. Details on the specific MoCA items are as 
follows. The short-term memory recall task (5 points) involves two learning trials of five 
nouns and delayed recall after approximately 5 minutes. Visuospatial abilities are assessed 
using a clock-drawing task (3 points) and a three-dimensional cube copy (1 point). Multiple 
aspects of executive functions are assessed using an alternation task adapted from the Trail 
Making B task (1 point), a phonemic fluency task (1 point), and a two-item verbal abstraction 
task (2 points). Attention, concentration, and working memory are evaluated using a sustained 
attention task (target detection using tapping; 1 point), a serial subtraction task (3 points), and 
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digits forward and backward (1 point each). Language is assessed using a three-item 
confrontation naming task with low-familiarity animals (lion, camel, rhinoceros; 3 points), 
repetition of two syntactically complex sentences (2 points), and the aforementioned fluency 
task. Finally, orientation to time and place is evaluated (6 points). The Digit Symbol 
Substitution Test (DSST), a subtest of the Wechsler Adult Intelligence Scales is a measure of 
psychomotor performance scored as the translation of numbers (1–9) corresponding to novel 
symbols in 90 seconds, with a maximum score of 9319,20.  
A summary of these cognitive tests as well as others are mentioned in Table IV. 
 
II.3. Frequency of cognitive impairment 
 
The frequency of CIND and dementia and the measurement tools found in population-
based studies throughout the world are shown in Table V.  
 
Based on the United Nations predictions for dementia, the number of demented people in the 
world will increase from 25.5 million in 2000 to 63 million in 2030 and to 114 million in 2050.
 In Canada, there are 60 150 new cases of dementia each year and there are currently 
about 450 000 people with all forms of dementia24. The Canadian Study of Health and Aging 
(CSHA), a large population study of cognition (n= 10,263), has estimated the prevalence of 
dementia25 and CIND3 to be 8 and 16.8% in the population over age 65, respectively. The most 
common types of dementia are Alzheimer disease and vascular dementia.   
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The Italian Longitudinal Study of Aging reported a prevalence of dementia and CIND 
of 10.7 and 5.5 % respectively in subjects between 65 and 84 years old 26. In the Kungsholmen 
project done in 2368 older adults in Stockholm, Sweden, the authors found 14.7% of subjects 
over 75 years old with CIND (n=1,435)27 and 5 % with dementia (n=1,810)28.  
 
In the Taiwanese nationwide population-based cross-sectional survey (n=10,432), 18.76 
% adults aged over 65 years had CIND and 8.04 % had dementia29. The prevalence of cognitive 
impairment ranged from 22.4% for participants in the Cardiovascular Health Study30(n=5,201, 
aged 65 and older) to 21% in the Established Populations for Epidemiologic Studies of the 
Elderly in the United States, with participants aged 71 years and older and cognitive function 
assessed by the Short Portable Mental Status Questionnaire (SPMSQ). 
 
Reported rates of CIND ranged widely mainly because of use of different measurement 
tools and cut-offs, different age groups, and different inclusion criteria.   
 
II.4. Economic consequences of severe cognitive impairment 
 
Canadian researchers have estimated the cost of caring for patients with severe cognitive 
impairment. Alzheimer disease is not only devastating to both patients and affected families but 
also is a considerable financial burden on society, particularly as the disease progresses. In 
Canada, it is estimated that the annual economic burden is $10 000 for each person with mild 
Alzheimer disease and $37 000 for severe Alzheimer disease31. For every person with dementia 
who does not live in a long term care facility, there is also the burden to the caregiver, which 
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usually falls on the patient’s spouse or child31. Caregivers often suffer significant health 
problems themselves due to the stress of taking care of a person with dementia31. 
 
II.5. Disability consequences of cognitive impairment 
 
Cognitive impairment can lead to disability and premature mortality. The 10-year 
trajectories of incident disability in the Iowa Established Populations for Epidemiological 
Studies of the Elderly cohort which included 3,673 participants aged 65 and older found that in 
people with MCI without instrument activity of daily living (IADL) limitations. IADL disability 
is defined as difficulty or dependence with any of three instrumental activities (shopping, 
preparing meals, or doing housework).the probability of ADL disability was the same as in the 
cognitively normal group. However, individuals with MCI plus prevalent IADL disabilities 
were much more likely to develop ADL disability, a prerequisite for a diagnosis of dementia32. 
 
A UK study of older people aged 75 years and over, showed that increased cognitive 
impairment at baseline was associated with an increased 5-year risk of physical disability on 
five activities of daily living (ADL)33. 
 
In the Manitoba Longitudinal Study on Ageing, good mental status measures at baseline 
were associated with a higher odds of successful aging including functioning well at home over 
a 12-year period, in 3,573 representative sample of elderly individuals aged 65-84 years34. In 
the PAQUID study, a study over one year follow-up consisted in 1850 subjects aged 65 and 
over, absence of cognitive impairment assessed by MMS at baseline was associated with 
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recovery to independence on activities of daily living and mobility in subjects initially 
dependent35. 
 
In the Canadian Study of Health and Aging (CSHA) data from 9,008 community-
dwelling individuals aged 85 years and older, Griffith et al found higher population 
attributable risk (PARs) for cognitive impairment in the older age groups and for men for 
disability in terms of ADL and IADL72. 
 
In a Dutch study36, cognitive impairment (MMSE ≤18) was found to account for 24% of 
walking disability in the oldest group of elderly.  Two studies from Hong Kong37 and Sweden38 
indicated that dementia had a PAR of 23.2 and 49.2% for functional disability in the elderly 
based on ADL. Dodge et al. also reported PARs ranging from 18.7 to 36.3% for different 
components of ADL among community-dwelling Japanese elders39. 
   
Survival rates for MCI patients, aged 85 years and older, over a 7-year period were midway 
between those for normal elderly people and Alzheimer’s disease patients, with a cumulative 
mortality risk twice that of the general population40. Obviously, cognitive impairment is a major 
cause of disability and premature mortality.   
II.6. Prevention 
Fortunately, there are some ways to prevent cognitive impairment. The identification of people 
at potential risk of dementia to begin early therapeutic intervention is important, because it may 
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lessen distress for both patient and family, minimise the risk of accidents, prolong autonomy, 
and perhaps even ultimately prevent the onset of the dementia process itself. 
 
Neurologists suggest that physical, leisure activities, and mentally stimulating activities, 
have separate effects in decreasing cognitive decline and reducing Alzheimer's disease risk41,42. 
Studies consistently agree on a significant protective effect of cognitive leisure activities 
(CLA)43,44.  Scarmeas et al, in a total of 1,772 non demented individual’s aged 65 years or older, 
living in northern Manhattan, New York, found that the risk of dementia was decreased in 
people who participated in more leisure activities (RR= 0.62; 95% CI 0.46 to 0.83)41. 
 
In a Swedish community-based study, the Kungsholmen Project, conducted in 776 
subjects, aged 75 years or more who were, cognitively intact at baseline and followed for 6 years 
(2 waves), it was found that stimulating activity, either mentally or socially oriented, may protect 
against dementia45. Adjusted relative risks for mental, social, and productive activities were 0.54 
(95% confidence interval (CI): 0.34, 0.87), 0.58 (95% CI: 0.37, 0.91), and 0.58 (95% CI: 0.38, 
0.91), respectively45.  
Wilson et al, in a study 6158 persons aged 65 years and older followed for 4 years, found 
that a one-point increase in the cognitive activity score was associated with a 64% reduction in 
risk of incident AD (OR = 0.36; 95% CI 0.20 to 0.65). Conversely, weekly hours of physical 
activity (mean 3.5; SD 5.1) were not related to disease risk (OR = 1.04; 95% CI 0.98 to 1.10) in 
a logistic regression model adjusted for age, education, sex, race, and possession of the APOE 
ε4 allele46. 
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The German Interdisciplinary Longitudinal Study on Adult Development and Aging 
(ILSE)47, which includes a representative birth cohort of 1002 participants with an average age 
of 74 years who were cognitively unimpaired at baseline and followed for an average time 
period of 12 years with three examination waves. Sattler et al found that people with a high 
cognitive activity score had a reduced risk of developing MCI and AD at time 3 by 62% 
compared to subjects whose cognitive activity was low at time 1 (OR=0.38, 95% CI 0.15–0.99, 
P=0.05) after adjusting for sex, education, socioeconomic status and depression47. 
 
In a longitudinal cohort study in 801 Catholic nuns, priests and brothers aged over 65 
years without dementia at enrollment who were recruited from 40 groups across the USA with 
a mean fellow-up of 4.5 years48, Wilson et al reported that for each 1-point increase in the 
cognitive activity score, there was a 33% decrease in the risk of developing AD48. To 
summarize, greater participation in cognitive activities appears to reduce the risk of developing 
dementia.   
 
 
II.7. Treatment 
II.7.1. Alzheimer’s disease: 
 
Available interventions do not cure the disease. Non pharmacologic interventions 
address behavioural troubles (like environmental modification, minimal excess stimulation, task 
simplification, etc.) and other possible treatable causes of cognitive impairment such as somatic 
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illness (e.g. hypothyroidism and anaemia), medication side-effects, modifiable cerebrovascular 
risk factors (e.g. diabetes, hypercholesterolemia and high blood pressure), psychiatric illness 
(e.g. depression, heavy drinking) and vitamin deficiency (e.g. B12 and folate)4. 
 
Cholinesterase inhibitors (donepezil, rivastigmine, and galantamine) are approved for 
the treatment of mild to moderate AD and have been reported to have efficacy. The three 
available cholinesterase inhibitors in North America are approved for treatment of Alzheimer's 
disease, not MCI. Many placebo-controlled trials, included participants with mild to moderate 
dementia and an average age of 74 years, found that the cholinesterase inhibitors are able to 
slow or to stabilize decline in cognition, function, behaviour and global change compared with 
placebo49-68. Evidence to demonstrate whether one of these drugs is more efficacious than 
another is limited, although adjusted indirect comparisons suggest that donepezil and 
rivastigmine may be slightly more efficacious than galantamine. The frequency of adverse 
events (the most common are nausea, vomiting, diarrhea, dizziness and weight loss) reported in 
trials, were lowest for donepezil and highest for rivastigmine69.  
Interventions designed to support caregivers in their role such as skills training, 
education to assist in caring for a person living with dementia can resolve problems including 
depression and strain, social isolation, ﬁnancial burden and disruptions to sleep70. 
 
II.7.2. Mild cognitive impairment 
Non pharmacological intervention:  
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In a randomized trial that used the Cognitive Subscale of the Alzheimer’s Disease 
Assessment Scale to compare the effect of a physical exercise program (brisk walking for 150 
minutes per week) with that of usual care and education in persons with subjective memory loss, 
the exercise group had better cognitive function at 6 months (the primary study outcome), with 
some residual benefit noted at 18 months71. 
 
Carter et al found that in stroke patients receiving cognitive skills remediation training 
mainly in the auditory attention task, followed by visual spatial perception, and correlated 
significantly with greater improvement in personal hygiene, bathing, and toilet activities. 
However, recovery in ADL performance depends in part on previous cognitive functioning72. 
 
In the PAQUID study (n=3,777, aged 65 years or older), regular participation in leisure 
activities was also found to be associated with a lower risk of subsequent dementia72,73. There 
is thus increasing evidence that staying physically and mentally active reduces the risk of 
cognitive decline and Alzheimer's disease41,42. 
 
Pharmacological intervention: Many medications like acethycholinesterases inhibitors 
(AChEIs) (donepezil, galantamine, rivastigmine) have been studied for an effect on MCI. 
AChEIs may improve cognitive function and global functioning in the short term with small 
pooled magnitude changes although they do not yet have government approval. In a randomized 
clinical trial, Petersen et al found that the donepezil group had a significantly reduced risk of 
progression to AD during the first 12 months of the study but not at later time points compared 
with the placebo group74. To date, donepezil is the only agent found to delay the progression 
 15 
from MCI to AD, although the data were derived from a single randomized, placebo-controlled 
study. 
 
Other medications have also been evaluated such as memantine, low dose aspirin, 3-
hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (simvastatin and atorvastatin), non-
steroidal anti-inﬂammatory drugs (ibuprofen, naproxen, indomethacin, and celecoxib), gonadal 
steroids (estrogen with or without progesterone and testosterone), Ginkgo biloba, stimulants 
such as Ritalin, and dietary supplements (multi-vitamins, vitamin B, vitamin E with or without 
vitamin C and ω-3 fatty acids)3. None of the trials found a beneﬁt for any of these medications 
or supplements on cognitive or physical function in persons with mild to moderate dementia or 
MCI nor did they prevent the progression of MCI or AD75. 
There is no current treatment for MCI sufficiently substantiated to have obtained 
government approval. A patient with MCI should be informed and told of the increased risk of 
progressing to dementia. The physician should closely follow the patient over time. Reversible 
causes of memory loss should be investigated and treated3.  
 
II.8. Relation between eye disease and cognitive decline 
II.8.1. The three eye diseases 
II.8.1.1. AMD 
II.8.1.1.a. Definition 
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Age-related macular degeneration (AMD) is the leading cause of permanent visual loss in 
western industrialized countries. Age-related macular degeneration begins by the formation of 
sub-retinal pigment epithelial yellowish deposits called drusen. Using a modification of the 
Wisconsin AMD grading system76, early AMD is characterised clinically by soft drusen 
accumulations and pigmentary abnormalities in the retinal pigment epithelium (RPE) and 
Bruch’s membrane, whereas late-stage manifestations are defined by atrophy of photoreceptors 
and the RPE underlying it, choroidal neovascularisation, subretinal haemorrhage, detachment 
of RPE and retinal scarring77. 
 
 The international consensus classifies late AMD into two well-defined clinical forms: a wet 
and dry form. Choroidal neovascularization is characteristic of the wet form, a stage found in 
approximately 20% of cases78-80. Although both forms of AMD can cause visual loss, the wet 
form accounts for approximately 90% of serious visual loss78-80. It is also generally accepted 
that the wet form of AMD follows and arises from the dry form (geographic atrophy). AMD 
was responsible for 21% of all cases of legal blindness in North America81. 
 
II.8.1.1.b. Prevalence  
 
According to data from the World Health Organization, AMD is currently considered 
the third leading cause of blindness worldwide (only behind cataract and glaucoma) and it 
accounts for 8.7% of blind persons globally82,83. The prevalence of AMD is reported to be 
negligible at age 50 years and approaches 6% at 80 years84. 
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In Canada, nearly 1 million individuals currently have early AMD, and approximately 
250 000 have advanced forms of the disease85. The National Coalition on Vision Health in 
Canada predict a 111% increase in the incidence of AMD by 2030. 
 
II.8.1.1.c. Risks factors 
 
Older age has been identified as the major risk factor in multiple epidemiological studies. 
In the Beaver Dam Eye Study86 (n=4926, aged 43 to 86 years), Rotterdam Study87 (n=6476, 
55-106 years), and Blue Mountains Eye Study (n=4926, 43-86 years)88, AMD prevalence was 
strongly age-related. Overall, AMD was present in 0.2% of the combined population aged 55 
to 64 years, rising to 13% of the population older than 85 years. Prevalence of neovascular 
AMD increased from 0.17%, among subjects aged 55 to 64 years, to 5.8% for those older than 
85 years61,62,63. 
 
In the Los Angeles Latino Eye Study (LALES) (n=6357, 49-97 years), prevalence of 
advanced AMD increased from 0% in those 40–49 years of age to 8.5% in those 80 or older89. 
In the Baltimore Eye Study(n=5308, 40 years or older), age was strongly associated with 
increasing prevalence of drusen, with rates ranging from about 10% among blacks and whites 
in their 40s, to over 30% among those in their 80s90. 
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Many population-based prospective studies showed that AMD prevalence varied with 
ethnic background. The Salisbury Eye Evaluation, which included large numbers of both whites 
and blacks, found that geographic atrophy was more common in whites than in blacks (1.8% 
compared to 0.3%)91. 
 
An analysis of the participants in the Multi-Ethnic Study of Atherosclerosis (MESA) 
(n=6814) showed a prevalence of combined early and late AMD in persons aged 45 years to 85 
years to be 2.4% in African Americans, 4.2% in Hispanics, 4.6% in Chinese-decent individuals, 
and 5.4% in whites92. 
 
There does not appear to be a gender difference in AMD once age is taken into account 
although there is a suggestion that neovascular AMD may be more common in women according 
to a recent meta-analysis93. In LALES, there was no significant age-adjusted gender difference 
in advanced AMD65.  
 
 
Smoking is a strong and consistent risk factor for age-related macular degeneration in 
multiple epidemiological studies. The LALES89, Beaver Dam94, Rotterdam95, Blue Mountains96 
and t h e  F unagata Study73 studies found a significant association of cigarette smoking for both 
the early and advanced forms of AMD with statistically significant odds ratios of 2.4, 3.1, and 
4.2 for the Beaver Dam, Rotterdam and Blue Mountains populations, respectively84. In The 
Funagata study, current smoking remains highly prevalent among Japanese men (36.8% of 
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participants in this study), which translates to a 66% population-attributable risk for late AMD 
cases in Japanese men that are attributable to their smoking behavior97. 
Cardiovascular risk factors (e.g., atherosclerosis44,46,47, hypertension98) have been linked with 
advanced AMD.   
 
Ocular risk factors for age-related macular degeneration include darker iris pigmentation, 
previous cataract surgery61 and hyperopic refraction60,62,64. Pooled data from the Blue Mountains 
and Beaver Dam eye studies found an association between cataract surgery and advanced 
AMD99,100, as too did pooled data from the Salisbury Eye Evaluation Survey101 and the 
Baltimore Eye Survey77.  In the Rotterdam study, for each diopter increase in hyperopia (near 
vision is blurred), there was a 5% increase in the risk of developing incident AMD102. Data 
from cross-sectional studies102-105 showed that hyperopic eyes are associated with higher odds 
of AMD, whereas myopic eyes are associated with lower odds of prevalent AMD compared 
with emmetropic eyes (normal visual acuity). 
 
There is strong evidence for the involvement of genetic factors on the development of 
age-related macular degeneration.  Early studies showed that familial history was a risk factor  
For AMD. For  example ,  the  Beaver  Dam Eye Study found that  having an  
older  s ib l ing wi th  AMD increased the  r i sk  of  having AMD in  the  younger  
s ibl ing 106. More recent studies have identified several genes that may play a role in 
AMD such as ABCA4 (ABCR)107, FBLN5108, HEMICENTIN-1 (FBLN6)109,110, and 
APOE111-113. Very strong evidence exists for the involvement of the complement factor H 
gene114,115. 
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II.8.1.1.d. Treatment of AMD 
 
The use of antioxidant nutrients is protective against progression of dry AMD.  
This is because oxidative damage from different sources like light exposure, 
inflammation and local production of reactive oxygen species to the retina has been 
strongly implicated with AMD. It has been reported in the Age-Related Eye Disease 
Study Research trial (AREDS) that the AREDS supplements reduce the risk of 
progression of AMD in people with the dry form of the disease116. A systematic review 
supports the association of dietary lutein/zeaxanthin (LZ) intake and reduced risk of 
late AMD117.  The Blue Mountains Eye Study and the Rotterdam Study researchers 
documented similar findings118,119.  
 
For the wet form, the two most frequently used drugs are ranibizumab and 
bevacizumab. Aflibercept has also been recently approved by Health Canada.  All of 
these drugs inhibit vascular endothelial growth factor, which is involved in 
angiogenesis120,121.  
II.8.1.2. Glaucoma 
  II.8.1.2.a. Definition 
 
After cataract, glaucoma is the second leading cause of blindness worldwide and the 
number one cause of irreversible vision loss122.  Glaucoma is characterized by a distinctive loss 
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of retinal nerve fibres and optic disc changes with the common feature of an optic neuropathy. 
Glaucoma can lead to an irreversible loss of visual field, usually beginning paracentrally, and 
after can progressively affect central visual field123. 
           Glaucoma can be divided in two types: open angle or angle closure and the causes can 
be primary, secondary or congenital. 
 
II.8.1.2.b. Prevalence of Glaucoma and Its Risk Factors 
 
In 2006, the number of individuals estimated to be bilaterally blind from glaucoma was 
projected to increase from 60.5 million in 2010 to 79.6 million by 2020122. There are 
approximately 409 000 people with glaucoma in Canada. A meta-analysis of 5 self-report 
surveys indicated that the prevalence of glaucoma was 2.7% for Canadians aged 40 years and 
11% for those aged 80 years based on data from  2002 and 2003124. 
The prevalence of the various types of glaucoma vary by race/ethnicity.  
 
Primary open angle glaucoma (POAG) alone is responsible for approximately 12% of 
all blindness in the world and 32% of the blindness in those of African descent125. In the United 
States, 1.9% have POAG126 while only 0.1% have PACG (primary angle closure glaucoma)127 
in people older than 40 years. The primary risk factors for POAG are elevated intra-ocular 
pressure (IOP), advancing age, family history of glaucoma, and race. 
In the Blue Mountains Eye Study, POAG prevalence was 8.2% in over 80 age group compared 
with that of the younger age groups128.  
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Primary angle closure glaucoma (PACG) is more common in Asian people100. As of 
2001, it was calculated that 4.5 million people were suffering from PACG in China129. Global 
projections estimate that by 2010 there will be approximately 15.7 million people with PACG, 
with half of them in China122. 
 
The risk factors for PACG are axial hyperopia130, family history of angle closure131, advancing 
age132, female gender133, race (Asian134, Latino127 and Inuit135 ancestry), shallow peripheral 
anterior chamber136 and short axial length of the eye137. Women are affected more than men 
(55% of open angle glaucoma, 70% of angle-closure glaucoma, and 59% of all glaucoma). 
Refractive error is a risk factor for the 2 types of glaucoma138,139. 
 
 
 
II.7.1.2.c. Treatment of glaucoma 
 
Treatment should be based on the type and cause of glaucoma. The only clinically 
established method of treating glaucoma is lowering IOP with the identification of a target IOP 
which needs to be reevaluated and documented at each visit123. The effectiveness of IOP 
lowering in the treatment of glaucoma has been established in several well-designed prospective 
RCTs.11,12,48,49 Therapeutic options are the use of topical or systemic medications to lower IOP 
(beta blockers, alpha-2 adrenergic agonists, and topical carbonic anhydrase inhibitors, miotics 
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and prostaglandin derivatives), laser trabeculoplasty, surgery to improve outflow facility, and 
cyclo-destructive laser to reduce aqueous production123. 
 
II.8.1.3. Fuchs corneal dystrophy 
II.8.1.3.a. Definition 
 
Fuchs corneal dystrophy (FCD) is a slowly progressive late-onset disorder.  
Characteristic features include the formation of focal excrescences of Descemet membrane 
termed guttae, loss of endothelial cell density and end-stage disease manifested by corneal 
edema and the formation of epithelial bullae140. Patients often present in the fifth to sixth decade 
of life.  It is an inherited autosomal dominant disorder with incomplete penetrance. Women are 
disproportionately more frequently affected compared to men140,141. 
 
II.8.1.3.b. Prevalence of Fuchs 
 
Few studies have been performed to assess the prevalence or incidence of this disease. 
FCD may affect as much as 4% of the American population over the age of 40 years142 . 
However, in one genetically isolated population on Tangier Island in Virginia, a sample of half 
the inhabitants over the age of 50 suggested a prevalence rate as high as 11% 143. A cross  
sectional study of 774 participants in the Reykjavik Eye Study in 2005 revealed 11% of females 
and 7% of males with guttae144. An examination of 107 patients with cataract in Japan revealed 
four (3.8%) with ‘primary cornea guttata’, described as early signs of FCD145 . A comparison of 
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the prevalence of cornea guttata between Japan and Singapore found a significantly increased 
prevalence of disease in Singapore (8.5 vs 5.5%) and decreased mean endothelial cell counts 
among its affected individuals relative to Japan146 . 
 
Some risk factors are cited like UV radiation144 , smoking history of more than 20 pack-
years144, chronic diseases, axial hypermetropia, shallow anterior chamber angle closure 
glaucoma147,148 and  AMD149.  Genetic factors have also recently been identified150. 
 
 II.8.1.3.c. Treatment of Fuchs 
 
The medical treatment of FCD is utilized to treat symptoms of early disease. By 
increasing external osmolality, hypertonic sodium chloride drops or ointment can be given to 
extract water from the cornea140.  To date, definitive treatment requires surgery. 
Surgery in FCD is performed for advanced disease. Penetrating keratoplasty has traditionally 
been the mainstay of surgical treatment, but the recent addition of Descemet stripping 
endothelial keratoplasty (DSEK) and other endothelial keratoplasties of the cornea offer new 
alternative procedures that are less invasive140.  
 
II.8.2. Studies examining relationship between AMD and cognition 
 
Several studies have investigated the relationship between AMD and cognitive 
impairment or AD with mixed results151  
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In the Rotterdam study, late stage AMD was associated with increased incident AD at 2-
year follow-up, after adjusting for age and gender (OR=2.1, 95% CI 1.1, 4.3) but this association 
was attenuated after adjustment for smoking and atherosclerosis (OR=1.5, 95% CI 0.6, 3.5)152. 
For early AMD, no association was observed in this study. The authors suggested that the 
relationship between AMD and AD was partially explained by shared cardiovascular risk 
factors.  
 
Another cross-sectional analysis from the Blue Mountains Eye Study showed that 
persons with late AMD were more likely to have cognitive impairment, as defined by the Mini-
Mental State examination, even after excluding vision related tasks from the examination36. 
However, no association was observed between MMSE and early AMD and a borderline non-
significant association of low scores on the modified MMSE (3MSE) with early AMD151. 
 
The Age Related Eye Disease (ARED) study found that reduced vision due to advanced 
AMD was associated with worse cognitive function scores as measured by the Modified Mini-
Mental State Examination and letter and verbal fluency tasks. (OR = 2.88; 95% CI = 1.75-4.7], 
after adjustment for age, sex, race, education, smoking status, diabetes mellitus, use of 
cholesterol-lowering medications, antioxidants, and hypertension. 
 
In the Cardiovascular Health Study, persons with low Digit Symbol Substitution Test 
(DSST) scores (lowest quartile of scores, ≤30) were more likely to have early AMD (OR = 1.38; 
95% CI =1.03-1.85) than persons with higher DSST scores after controlling for age, gender, 
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race, and center. This association was stronger (OR = 2.00; 95% CI = 1.29-3.10), in analyses 
further controlling for education, systolic blood pressure, total cholesterol, diabetes, smoking 
status and APOE genotype153. 
 
Saido and Iwata154 report in their review article that ageing of the brain causes abnormal 
proteolysis, resulting in abnormal deposits of proteins (senile plaque and drusen) followed by 
progressive neuronal dysfunction and degeneration in AD and AMD patients respectively. These 
results are supported by Ohno-Matsui155. 
 
In the ARIC population (aged 45-64 years, n=9286), where standardized protocol to 
assess AMD signs was used, an association between cognitive impairment, defined as Word 
Fluency Test scores in the lowest 10% of the population, with early AMD was reported. 
However, the ARIC study found no association between DSST and early AMD156. 
 
Proitsi and his colleagues found that there is not an association between well replicated 
AMD genetic risk factors and AD157. 
The Singapore Malay Eye Study, a cross-sectional population-based study, did not find 
an association between AMD and cognitive dysfunction158. 
Several biological hypotheses have been proposed to explain the link between AMD and 
AD: 
1) Both diseases have similar histopathological changes159. In AMD and AD, there an 
accumulation of drusen and senile plaque and each containing extracellular β-amyloid. 
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2) AMD and AD share similar vascular risk factors, such as hypertension, cigarette 
smoking and stroke. 
3) There is evidence of shared genetic loci such as the apolipoprotein E 4 allele, which is 
positively associated with Alzheimer’s disease but inversely with AMD159. 
 
II.8.3. Studies examining relationship between glaucoma and cognition 
 
Several studies have also investigated the relationship between glaucoma and cognitive 
status with mixed results. Two case–control studies have shown a higher proportion of glaucoma 
among AD patients compared to the control participants160,161.  
 
The strongest support for a relationship comes from The Three-City–Bordeaux–Alienor 
study, population-based prospective cohort study that showed that participants with an POAG 
were four times more likely to develop dementia during the 3-year follow-up period (OR = 3.9; 
95% CI = 1.5–10.4; p = 0.0054) after adjustment for age, gender, education, family history of 
glaucoma, vascular comorbidities, and apolipoprotein E4162.  Dementia was determined by a 
neurologist.   
 
Clinical data and experiments on human eye tissues have consistently supported 
common AD and glaucomatous retinal pathology. Histopathologic analyses of enucleated 
glaucomatous eyes have shown evidence of substantial retinal ganglion cell (RGC) loss 
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compared to controls, while a higher proportion of patients with AD showed abnormalities in 
the retinal the nerve fiber layer (NFL)159. 
 
Other studies investigating a link between glaucoma and cognition have been negative.  
A retrospective cohort study done using Medicare claims data did not find a relationship 
between diagnosed glaucoma and Alzheimer’s disease163. Kessing et al also report no 
association between glaucoma and Alzheimer’s disease using a nationwide case register in 
Denmark164.  The cross-sectional population-based study of 1179 older adults mentioned above 
did not find an association between glaucoma and cognitive dysfunction as measured by the 
Abbreviated Mental Test158.   
 
To summarize, studies are not in agreement on whether glaucoma and cognitive 
impairment are related.  One possible reason is that up to 50% of glaucoma cases are not 
diagnosed so studies relying on medical records to diagnose glaucoma may suffer from 
misclassification to different degrees.   
 
Beyond clinical observations, several biological hypotheses have been proposed to 
explain a possible link between glaucoma and AD.  
1-One is related to an abnormal difference of pressure between cerebrospinal fluid 
pressure and IOP, that damages the optic nerve165 . 
2-changes in the cerebrospinal fluid composition, particularly in the subarachnoid space 
of the optic nerve, could lead to abnormal accumulation of proteins (b-amyloid) that have 
potential toxic effects on optic nerve166. 
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           3- Some studies have shown that apolipoprotein E 4 allele may be a latent risk factor in 
the development of primary glaucoma. But these results are controversial with other 
studies161,167-170.  
4-Other possible mechanisms, such as retinal vessel abnormalities171 and Helicobacter 
pylori infection172, have also been proposed. 
 
II.2.3. Need for further research 
 
 There have been limitations in prior research investigating the link between eye disease 
and cognitive status.  Many studies did not include sufficient numbers of people with late AMD 
or they did not have adequate data on confounders to properly adjust.  Many of the glaucoma 
studies relied on glaucoma diagnoses from a doctor rather than doing eye exams on all 
participants.  Furthermore, results were conflicting.   
 
The research presented in this thesis will significantly add to the existing literature because it 
used large numbers of patients with late AMD, glaucoma, and Fuchs corneal dystrophy, it used 
people with normal vision who had comprehensive eye exams as a control population, and it 
collected data on numerous potential confounders.   
 
CHAPTER III       SAMPLE SIZE CALCULATION 
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For the MMSE-Blind version test, we required 64 people per group in order to detect a 
difference of 1 unit between groups assuming standard deviations in each group of 2.0, 80% 
power, and 5% Type 1 error. This calculation was made using PS Power and Sample Size 
program. Data used for these calculations are based on reasonable assumptions based other 
literature, and what we believed to be clinically significant differences.   
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ABSTRACT 
 
Purpose : To determine whether people with age-related eye disease have lower cognitive 
scores than people with normal vision.    
 
Methods : A hospital-based cross-sectional study was performed in which people from the 
ophthalmology clinics at Maisonneuve-Rosemont Hospital (Montreal, Canada) were recruited 
who had either age-related macular degeneration (AMD), Fuch’s corneal dystrophy, or 
glaucoma.  Controls, recruited from the same clinics, did not have significant vision loss.  
Cognitive status was measured using the Mini-Mental State Exam Blind Version (range 0-22) 
which excludes 8 items that rely on vision.  Linear regression with bootstrapped standard errors 
was used to adjust for demographic and medical factors.  
 
Results : People with AMD, Fuch’s corneal dystrophy, and glaucoma had lower cognitive 
scores, on average, than controls (P<0.05). These relationships remained statistically significant 
after adjusting for factors such as age, gender, race, education, living alone, systemic 
comorbidities, and lens opacity.   
 
Conclusions : People with three different age-related eye diseases had lower cognitive scores.  
Reasons for this should be explored using longitudinal studies and a full battery of cognitive 
tests that do not rely on vision.   
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INTRODUCTION 
 
 Cognitive impairment is an acquired deficit in memory, problem solving, orientation, or 
abstraction.  Several epidemiological studies have indicated that people with age-related eye 
diseases like age-related macular degeneration (AMD) or glaucoma have reduced cognitive 
scores1,151,153,158,160,161,173. Other studies found a null relationship 158,163,164.  Methodological 
limitations plagued some of the studies such as not having adequate numbers of people with 
late-stage AMD, lacking a uniform visual exam for cases and controls, or limited adjustment for 
confounding. In support of the studies that found a positive relationship, there are also biological 
similarities between eye diseases like AMD and glaucoma, and the major cause of dementia, 
Alzheimer’s disease.  Sivak et al provide a review of research noting similarities between the 
three diseases such as retinal damage, amyloid β deposition, pTau, oxidative and metabolic 
stress, and glial reactivity 159.  
  
Given the lack of consistent epidemiological results on this topic, we examined this issue by 
recruiting people with one of three age-related eye diseases that differ in which part of the visual 
system is affected. The three eye diseases that we included were AMD, glaucoma, and Fuch’s 
corneal dystrophy. We hypothesized that all three groups would have worse cognitive scores 
than our control group with normal vision after adjusting for potential confounders.  
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METHODS 
Study Design and Population 
 
All participants were recruited from the ophthalmology clinics of Maisonneuve-
Rosemont Hospital in Montreal, Canada between September, 2009 and September, 2013.  
Research personnel reviewed patient files each day for 5 retinal specialists, 5 glaucoma 
specialists, 4 corneal specialists, and 6 general ophthalmologists to check for eligible patients 
who were then approached in the waiting room regarding participation.  It is a sub-study from 
mobility study. This study was not designed to evaluate cognition as a primary outcome. To be 
eligible for this cross-sectional study, participants had to be 65 years or older. Participants had 
to have either no significant vision loss (controls) or one of three age-related eye diseases:  age-
related macular degeneration (AMD), Fuch’s corneal dystrophy, or glaucoma. Each group had 
to meet certain visual criteria as well. The AMD and Fuchs patients were required to have 
bilateral disease and to have visual acuity of worse than 20/40 in their better eye. Glaucoma 
patients were required to have bilateral disease and to have a visual field mean deviation worse 
than or equal to -4dB in their worse eye. This would be considered “early” visual field loss 
according to prior literature174. All glaucoma types were recruited. The 3 groups with eye disease 
were allowed to have other eye diseases, which may have also impaired vision.  However, a 
person was not included if he/she met the visual inclusion criteria for multiple groups (i.e. AMD 
and Fuchs). Finally, the controls were required to have visual acuity of 20/40 or better in the 
better eye and a visual field mean deviation in the worse eye better than -4dB. Controls either 
had no current eye disease (67%) or they had non-visually impairing conditions such as early 
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cataract (15%), early AMD (3%), ocular hypertension (5%), blepharitis (3%), or other (6%).  
People who had received eye surgery, laser, or an intra-vitreal injection in the last 3 months 
were enrolled after a 2-3 month delay so that their data would be less affected by their treatment 
and recovery. 
 
There were 776 people who appeared to meet eligibility criteria from a review of the 
medical records.  Of the 776 people, 518 (67%) people accepted our invitation to be in the study, 
208 (27%) refused, and 50 (6%) were not capable of responding for themselves.  Of the 518 
who accepted, 420 people met final eligibility criteria including 113 with age-related macular 
degeneration (AMD), 130 with glaucoma, 66 with Fuch’s corneal dystrophy, and 111 people 
without significant eye disease. Participants were paid $10 for their participation and signed a 
consent form. The project was approved by the Ethics Committee of the Hospital and the 
research conformed to the tenets of the Declaration of Helsinki.   
 
Data Collection 
 
 Data were collected from questionnaires, vision tests, and a review of the medical record.   
Cognitive status was measured using the Mini-Mental State Exam (MMSE) Blind 
Version which was validated by Busse et al 9. The Blind Version omits 8 items that directly or 
indirectly rely on vision. The MMSE Blind Version is a global test of cognition. Participants 
with scores less than 17 meet the criteria for cognitive impairment 9. Demographic information 
was collected on age, gender, ethnicity, and highest grade of education.  Participants were asked 
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if they lived alone and about the presence or absence of a physician diagnosis of 13 chronic 
conditions such as diabetes, heart disease, arthritis, asthma, chronic obstructive pulmonary 
disease, hypertension, chronic arterial insufficiency, stroke, Parkinson disease, depression, 
hearing loss, spine disease and hip fracture.   
 
Visual acuity was tested using the Early Treatment of Diabetic Retinopathy Study 
(ETDRS) chart with illuminated light box at 2 meters or at 1 meter if the participant could not 
read any letters at 2 meters175,176. Letter by letter scoring was performed with scores at 2 meters 
converted to scores at 1 meter by adding 15. Scores were converted to logMAR.  Contrast 
sensitivity was measured using the Pelli-Robson chart at 1 meter for each eye 177.  Forced choice 
letter-by-letter scoring procedures were used until a participant read all 3 letters of a triplet 
incorrectly. Visual field was measured using the Humphrey FDT test with full threshold N-30 
testing in each eye 178. The FDT measures 30˚ horizontally and 24˚ vertically.   
 
The medical record was reviewed and further detail on the patient’s eye disease and any 
coexisting eye disease (such as lens opacity) was recorded. Those who could not perform the 
FDT test because of advanced eye disease had their last visual field exam results taken from the 
medical record.   
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Statistical Analysis 
 
The primary outcome was the continuous score from the MMSE Blind test. The mean MMSE 
Blind scores were compared between the four groups (AMD, Fuchs, glaucoma, control) by the 
ANOVA test. Multiple linear regression was used to determine whether the groups with eye 
disease had worse cognitive scores adjusting for demographic and health factors that were 
considered potential confounders. Standard errors and 95% confidence intervals for the 
regression estimates were obtained from bootstrapping (2000 replicates) 179.  Analyses were 
done in Stata Version 11.0 (College Station, Texas).   
 
RESULTS 
 
We enrolled 420 people who resided in the community (82%), assisted living facilities 
(8%), and retirement homes (10%). Characteristics of the four groups are shown in Table 1.  The 
groups with age-related eye disease were older, had less education, and had more systemic 
comorbidities than the control group (P<0.05). The AMD and Fuchs groups had a greater 
percentage of women than the control group (P<0.05). The mean visual acuity of the AMD and 
Fuchs groups was 20/100 and 20/80 respectively. The mean visual field mean deviation in the 
better eye in the glaucoma group was –9.5dB.  
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The mean MMSE Blind scores were lower in the three groups with age-related eye 
disease than in the control group (P<0.001). Also, a greater percentage of people in the groups 
with eye disease had cognitive impairment compared to the control group (P=0.019).   
 
After adjustment for demographic and health factors (Table 2), all three groups with age-
related eye disease had lower MMSE Blind scores than the control group (P<0.05). The scores, 
in AMD, Fuch’s and glaucoma group, were 0.81, 0.82 and 0.72 lower than the control group, 
respectively. Other factors that were associated with worse cognition included older age, being 
of African descent, and living alone (P<0.05). Better education was associated with better 
cognition (P<0.001).   
 
In Table 3, we examined which measures of visual function were most strongly related 
to cognitive function. Contrast sensitivity and visual acuity were highly statistically significant 
(P<0.001, CI = (0.69, 2.1) and CI = (-2.11, -0.06) respectively) while visual field in the better 
eye had borderline statistical significance (P=0.09, CI = (-0.01, 0.08)). The placement of all 
three measures of visual function in the model together results in the loss of statistical 
significance for all three due to their colinearity.  
 
DISCUSSION 
 
 All three of the groups with age-related eye disease had lower cognitive scores when 
compared to a control group with good vision. This is despite the fact that the three diseases all 
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affect different parts of the eye, leading one to believe that the relationships may not primarily 
be due to common pathogenesis159. An alternative explanation is that the loss of vision at an 
older age leads to a lack of cognitive stimulation that over time is harmful to the brain. In fact, 
numerous observational studies have shown that participation in cognitively stimulating 
activities decreases the risk of cognitive impairment48,180,181. Furthermore, randomized clinical 
trials have found that cognitive training programs can improve cognitive function182,183. 
However, cognitive training programs typically require good vision and many cognitively 
stimulating leisure activities also require good vision or adapted materials (e.g. reading, playing 
cards, driving) making it difficult for people with vision loss to participate.  In fact, studies have 
found that older adults with lower levels of visual acuity have reduced levels of leisure-time 
physical activity184,185.   
 
Our results showing that glaucoma and Fuch’s corneal dystrophy are related to reduced 
scores on the MMSE Blind version are novel, to our knowledge. Our results confirm findings 
from the Blue Mountains Eye Study, which also found that people with late AMD had lower 
scores on the MMSE minus 5 items that relied on vision (the MMSE Blind Version that we used 
omits 8 items)151. The MMSE is a global cognitive test that was designed to detect dementia 
rather than to evaluate the full range of cognition for research purposes. Therefore, it suffers 
from a ceiling effect when used in populations who are relatively free of dementia.   Future 
studies should use a variety of cognitive tests that evaluate different domains of cognition and 
that can finely differentiate cognition in primarily non-demented people.  Longitudinal studies 
are needed to establish the temporality of the vision loss relative to the cognitive decline.   
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A strength of this study is that we had relatively large numbers of people with eye disease 
compared to the population-based studies that have previously been done.  Furthermore, our 
controls were recruited from the same clinics as the people with eye disease which helps to 
ensure their similarity.  In fact, the mean full scale MMSE score in our controls was 28 
(SD=1.6), which is identical to people of a similar age in population-based studies 186.  
Limitations include that our data are cross-sectional, that we only had a single cognitive test, 
and that we do not have data on certain potentially important confounders like smoking, diet, 
genetic factors, and atherosclerosis.  Future studies should include these factors.  
  
Reasons why age-related eye disease and cognitive decline are related need further 
investigation. Cognitive decline is a major risk factor for admission to nursing home facilities 
and a major cost to society187,188, and on top of visual impairment, would be doubly disabling.   
Efforts to better understand and prevent cognitive decline in people with poor vision are 
necessary.    
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TABLES 
Table I : Description of eye disease and control groups 
 AMD 
Mean (SD) 
or % 
n=113 
Fuch’s 
Mean (SD) 
or % 
n=66 
Glaucoma 
Mean (SD) 
or % 
n=130 
Controls 
Mean (SD) 
or % 
n=111 
P-
value* 
Demographics 
Age 
 
82.5 (6.4) 
 
78.5 (7.1) 
 
76.6 (7.6) 
 
74.0 (4.9) 
 
 
<0.001 
Female gender 75% 83% 58% 59% 
 
<0.001 
Ethnicity 
     Caucasian 
     African descent 
 
 
100% 
0% 
 
100% 
0% 
 
89% 
11% 
 
97% 
3% 
 
0.001 
Education, years 
Live Alone 
     Yes 
     No 
Eye measures: 
9.4 (3.4) 
 
53%  
47% 
 
10.9 (4.5) 
 
41% 
59% 
10.9 (4.2) 
 
32% 
68% 
11.8 (3.7) 
 
39% 
61% 
0.001 
 
0.008 
Binocularvisual    
acuity, logMAR 
 
0.71 (0.40) 0.59 (0.31) 0.27 (0.29) 0.04 (0.06) <0.001 
Logcontrast 
sensitivity in better 
eye, letters correct 
 
1.09 (0.41) 1.16 (0.34) 1.29 (0.34) 1.80 (0.15) <0.001 
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Visual field in 
better eye, MD in 
dB 
 
-3.1 (3.7) -2.9  (3.6) -9.5 (6.6) 0.5 (2.0) <0.001 
Lens Opacity 
Cognitive measures 
29% 26% 28% 15% 0.057 
Mini-Mental Blind 
Version (max 22) 
 
19.1 (2.6) 19.7 (2.6) 19.3 (2.9) 20.7 (1.4) <0.001 
Cognitive 
Impairment 
Comorbidities 
14% 14% 12% 3% 0.007 
Number of 
Comorbidities 
 
3.3 (1.9) 2.9 (1.9) 2.6 (1.6) 2.0 (1.5) <0.001 
  
 
 
 
 
 
 
 
 
* P-value derived from ANOVA for continuous variables or chi-square test/Fishers exact test 
for categorical variables 
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Table II: Relationships between age-related eye disease and cognitive status from linear 
regression model 
 Cognition 
β           
 
Bootstrapped 95% CI 
Eye Disease Group 
    Control 
    AMD 
    Fuch’s 
    Glaucoma 
 
 
 0.00 
-0.81 
-0.82 
-0.72 
 
 
 
-1.44, -0.17  
-1.49, -0.15 
-1.23, -0.20 
Age 
 
-0.06 -0.10, -0.03 
Gender 
    Male  
    Female  
 
 
0.00 
0.46 
 
 
-0.06, 0.97 
Ethnicity 
     Caucasian 
     African descent 
 
 
 0.00 
-2.25 
 
 
-3.80, -0.70 
Education 
 
0.21 0.14, 0.27 
Live Alone 
 
-0.61 -1.05, -0.16 
Number of Comorbidities 
 
-0.00 -0.14, 0.14 
Lens Opacity 
 
0.10 -0.44, 0.65 
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Table III : Multiple linear regression models showing adjusted relationship between three 
measures of visual function and cognitive status 
Model Visual Function Variable Cognitive Status 
β             95% CI 
Model 1* Binocular Logmar Acuity, per 1 unit 
 
-1.09     -2.11, -0.06 
Model 2* Log Contrast Sensitivity, per 0.1 unit 
 
1.40        0.69, 2.10 
Model 3* Visual Field in Better Eye, per dB 
 
0.04       -0.01, 0.08 
*All models also adjusted for age, gender, ethnicity, education, number of comorobidities, living 
alone, and lens opacity.   
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CHAPTER V  DISCUSSION 
 
V.1. Eye disease and cognitive decline 
 
All three groups with eye disease had lower cognitive scores than people with normal 
vision. There was not much difference in cognitive scores between those who had central vision 
loss due to AMD or Fuchs compared to those who had more peripheral vision loss due to 
glaucoma. Therefore, the type of vision loss did not seem to matter as much as the loss of vision 
itself regardless of its location. When we looked at the relationships between measures of visual 
function and cognition, the strongest relationship was found with contrast sensitivity followed 
by visual acuity and visual field.   
 
On average, the magnitudes of the lower cognitive scores were modest at about 0.7 to 
0.8 units on the MMSE Blind version after adjustment. However, it is important to remember 
that the MMSE-Blind has a ceiling effect so the difference might be much greater using a test 
that has a greater range of values on the higher functioning end. Furthermore, there were large 
differences in the percentages of people who had cognitive impairment, defined as a MMSE-
Blind score less than 17, as only 3% of those with normal vision had cognitive impairment 
compared to over 10% in those with each of the eye diseases.   
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V.2. Strengths and limits of the study 
 
 This study was novel in its recruitment of patients with three different eye diseases 
compared to a control group with good vision. No studies have been done to examine the 
relationship between eye diseases like glaucoma or Fuchs with cognitive function using the 
MMSE Blind version test. Cognitive function was measured by MMSE-Blind version test, 
which was validated by Busse et al against the full version. The test did not rely on vision 
because it omits 8 items that require image processing in a test situation (range 0-22). Data on 
potential confounders such as age, gender, ethnicity, living alone, comorbidities, education and 
lens opacity were also collected and included in the analysis. All potential patients were 
recruited from the same clinics and response rate was recorded. There was a representative 
sample of eligible patients from the clinic. There was a 67 % response rate in this study.   
 
There are some limitations of the study.  Because it was cross-sectional, one cannot make 
any assumptions regarding the temporality of the onset of eye disease and the onset of cognitive 
decline. A longitudinal design would have offered more insight in ascertaining the temporal 
order of circumstances surrounding the cognitive impairment. One concern about the inability 
to show temporality is the risk of reverse causality. It was hypothesized that patients with eye 
disease might reduce their stimulating activities because of their vision, leading to cognitive 
decline. However, it is also possible that patients who develop cognitive impairment due to other 
factors then go on to develop more severe eye disease due to an inability to properly care for the 
eyes.  Many studies have questioned whether AMD, glaucoma and cognition might share the 
same biological mechanisms (e.g. genes, abnormal protein deposits)159 and have discussed the 
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common mechanisms that can underlie all three diseases, with potential use of the retina as a 
biomarker for AD diagnosis and progression189,190.   So, they can coexist together and be latent 
until the patient or the physician discovers the pathology. This is why longitudinal data are 
needed to properly establish temporal relationships.    
 
No data on cognitively stimulating activities, on smoking and on genetic factors is 
another limitation as these factors may help to explain reduced cognitive function in people with 
eye disease.  Finally, another limitation was that this study was designed to examine mobility 
as a primary outcome-not cognition. Therefore, only one cognitive test was used which is a 
global test of cognitive function, has limited sensitivity to detect MCI, and has a ceiling effect 
in the highest value scores.  
 
V.3. Clinical implications and future research 
 
 This study is a first step in trying to understand the link between eye disease and 
cognitive function. The next steps will be to undertake longitudinal studies to better understand 
why this link exists. Longitudinal studies should include both biological and social factors to 
fully understand this link. Once we understand why eye disease and cognitive function are 
related, then we can educate patients about this risk and help them take steps to reduce their risk 
of cognitive decline. Currently, cognitive training programs require good vision to use them so 
they are of little help to people with low vision.   
This work and subsequent work on this topic is important patients, their families, their 
physicians, and low vision rehabilitation providers. Patients with eye disease may benefit from 
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knowledge that their cognitive function may be affected and that they need to monitor their 
cognitive health and take steps to improve it. Families of patients may also find this research 
beneficial.  They may take steps to make the living environment of the patient with eye disease 
more stimulating. Finally, rehabilitation providers may find this study useful in order to develop 
interventions that do not rely on vision to prevent cognitive decline. Moreover, older adults with 
eye disease may benefit from a comprehensive geriatric evaluation and the elaboration of a 
treatment plan to address modifiable non-visual risk factors for cognitive problems like 
benzodiazepine use.  
 
 This study is the first step for future longitudinal investigations to examine the trajectory 
of cognitive function over time and to understand the reasons for reduced cognition in people 
with eye disease. 
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i 
Table IV: Some cognitive tests used in research 
Measure Description/ rationale  Criterion 
MMSE (Folstein, 1975)6 Measure orientation to 
time and place, memory, 
attention, calculation,  
language and visual 
construction 
Total score max = 30 
MMSE Blind Version 
(Reischies and 
Geiselmann, 1997)8 
Measure orientation to 
time and place, memory, 
attention, calculation, and 
language. 
Total score max = 22 
the General Practitioner 
Assessment of Cognition 
(GPCOG), (Brodaty et al., 
2002)191 
Patient section measure 
time orientation, clock 
drawing, information and 
memory recall and 
informant section consist 
of eight historical 
questions  
Patient section: 
maximum score = 15 
 
Informant section 
(maximum score = 8). 
Memory Impairment 
Screen (MIS), (Buschke 
1999)10 
Measure word-recall task 
that tests encoding as well 
as retrieval 
 
The Abbreviated Mental 
Test (AMT) ( Hodkinson, 
1972)192 
Measure orientation 
semantic knowledge 
episodic memory delayed 
recall, picture naming and 
attention. 
Max score = 10 
Modified Mini-Mental 
State Examination(3MSE), 
(Teng et al., 1987)193 
Measure orientation, 
concentration, language, 
Max score = 100.37 
 
 
ii 
praxis and immediate and 
delayed memory 
The Cambridge Mental 
Disorder OF Eldery 
Examination (CAMDEX–
Section H) (Roth et al., 
1986)194 
 
Structured interview with 
the participant’s 
significant Other (i.e., 
informant) addressing the 
subject’s history 
1. Memory changes  
2. Changes in general 
mental function 
Yes, No 
 
WMS Information 
(Wechsler, 1974)197 
 
Measure of long-term 
recall  
 
Max score = 6 
Buschke Cued Memory 
Paradigm (Buschke, 1984; 
Tuokko and Crockett, 
1989)195,196 
 
Measure of short-term 
memory; free and cued 
recall conditions 
1. Free recall: Trial 1  
2. Total cued recall: Sum 
of cued recall trials 1–3  
3. Total free recall: Sum of 
free recall trials 1–3 
Total score; Max 
scores: 
Free = 12; Total 
cued = 36; Total 
free = 36 
 
WAIS-R Block Design 
(Wechsler, 1981)197 
 
Measure of visuospatial 
ability, construction, and 
motor function (short 
version [items 1–9]; odd 
items only) 
 
Total score; Max 
score = 30 
 
WAIS-R Similarities 
(Wechsler, 1981)197 
 
Measure of abstract 
thinking and verbal 
Total score; Max 
score = 14 
 
 
 
iii 
problem-solving (short 
version [items 1–13]; odd 
questions only) 
 
 
WAIS-R Comprehension 
(Wechsler, 1981)197 
 
Verbal measure of 
judgment (short version 
[items 1– 
15]; odd questions only) 
 
Total score; Max 
Score = 15 
 
 
Rey Auditory-Verbal 
Learning Test (Rey, 
1941)198 
 
Measure of short-term 
verbal memory 2 
1. List A: Trial 1  
2. List A: Trial 6  
3. Total recall list A: Sum 
of trials 1–5  
 
Total score; Max 
scores: 
Trials 1 ¼ 15; Trial 
6 ¼ 15; Total ¼ 75 
 
Controlled Oral Word 
Association Test (Spreen, 
1977 and Benton, 1969)199  
 
Measure of verbal fluency 
and cognitive flexibility 
( total number of words 
generated for words 
beginning with the letters 
F, A, and S). 
 
 
 
Benton Visual Retention 
Test (MC; Benton, 
1974)200 
 
Measure of nonverbal 
memory  
 
Number correct; Max 
Score = 16 
WAIS-R DIGIT Symbol 
Test (Wechsler, 1981)197 
Measure of attention, 
problem-solving, and 
processing speed 
Max Score = 93 
 
 
iv 
MoCA, (Yeo et al., 1997), 
Nasreddine et al., 2005) 
(Dong et al., 2010)18. 
Measure seven cognitive 
domains, both memory       
(verbal memory and visual 
memory) and the non-
memory domains 
(attention, language, 
visuomotor speed, 
visuoconstruction and  
executive function) 
Max score = 29 
The Trail Making Test, 
Part A( Spreen and Strauss 
1998)201 
Measure the speed of 
processing that involves 
visual scanning and 
psychomotor speed 
Time limit = 300 s 
The Clock Drawing test 
(Goodglass and Kaplan 
1983)202 
Measure semantic memory 
related time, number 
and/or linguistic facility 
and visual motor 
processing 
Max score = 6 points 
 
 
 
v 
Table V: The frequency of CIND and dementia and the measurement tools used from 
large population-based studies throughout the world 
Population based 
study 
Cognitive measurement CIND % Dementia % 
The Italian 
Longitudinal Study 
of Aging (n=3,425, 
65-84 years)26 
MMSE, CAMDEX section B 
and H, the Pfeffer Functional 
Activities Questionnaire, a 
neurological examination, 
review of clinical record. 
10.7 - 
The Canadian Study 
of Health and Aging 
(CSHA) (N=10,263, 
>65 years)3,25 
 100-point scale modified 
version of the 3MSE 
16.8 8 
In the Kungsholmen 
project >75 
years27,28  
-MMSE (CIND) 
- Phase I: MMSE, Katz 
index of ADL Phase II: 
Clinical examination, MMSE, 
ADL(dementia) 
(n=1,435) 
14.7 
(n=1,810) 
5 
Taiyuan Study 
(n=6,192, >65 years) 
MMSE, Boston Naming Test, 
Trail Making Tests A and B, 
Block Design, Rey Auditory 
Verbal Learning Test, Visual 
Reproduction, Logical 
Memory, letter and category 
fluency, the National Adult 
Reading Test, the Geriatric 
Depression Scale, and the 
‘‘state’’ section of the State-
Trait Anxiety Inventory 
9.7 
 
- 
 
 
vi 
the Cardiovascular 
Health Study   
> 65 years 
Modified Mini-Mental State 
Examination (3MSE) 16 and 
Digit Symbol Substitution Test 
(DSST). 
8.5 19.6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
vii 
Figure 1: Mini-Mental Status Exam Blind Version – English Version 
  
 
 
 
 
 
 
viii 
Figure 2 : Mini-Mental Status Exam Blind Version – French Version 
 
 
